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Abstract: Primary and recurrent venous thromboembolic disease (VTE, deep venous thrombosis and pulmonary embolism) 
remain a signiﬁ  cant source of morbidity and mortality in the hospitalized patient. Non-speciﬁ  c subjective complaints and 
lack of speciﬁ  c objective ﬁ  ndings related to acute deep venous thrombosis (DVT) and pulmonary embolism (PE) complicate 
the diagnosis. There remains no single serum marker available to exclusively conﬁ  rm the diagnosis of VTE. While D-dimer 
is highly sensitive and useful for diagnostic exclusion, it lacks the speciﬁ  city necessary for diagnostic conﬁ  rmation result-
ing in the need for a variety of additional studies (i.e.: duplex ultrasound, venography, V/Q scanning, helical thoracic and 
pelvic CT scans and pulmoary angiography). There is evolving research supporting the utility of various plasma markers 
as novel “biomarkers” for VTE including selectins, microparticles, interleukin-10 and other cytokines. This review attempts 
to examine recent literature assessing the utility of P-selectin, microparticles, D-dimer, E-selectin, thrombin, interleukins 
and ﬁ  brin monomers in the diagnosis and guidance of therapy for VTE.
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Introduction
Primary and recurrent venous thromboembolic disease (VTE, deep venous thrombosis and pulmo-
nary embolism) remain a signiﬁ  cant source of morbidity and mortality in the hospitalized patient 
with more than 900,000 primary and recurrent events occurring in 2002 (Table 1). Non-speciﬁ  c 
subjective complaints and lack of speciﬁ  c objective ﬁ  ndings related to acute deep venous throm-
bosis (DVT) and pulmonary embolism (PE) complicate the diagnosis. There is presently no single 
serum marker available to exclusively conﬁ  rm the diagnosis of VTE. The most widely accepted 
and utilized assay, D-dimer, is highly sensitive and therefore useful for exclusion of the disease 
but lacks the speciﬁ  city necessary to conﬁ  rm the diagnosis. For this reason additional studies 
including duplex ultrasound, venography, V/Q scanning, helical thoracic and pelvic CT scans and 
pulmonary angiography remain the standard for diagnosis. Currently, there is evolving research 
supporting the utility of various plasma markers as novel “biomarkers” for VTE including selectins, 
microparticles, interleukin-10 and other cytokines. While this review is not presented as a true 
metaanalysis, a Pubmed search was utilized and appropriate studies from 1990 to 2007 were 
critically reviewed.
P-Selectin
P-selectin (GMP-140) is an adhesion glycoprotein present in platelet α-granules and endothelial cell 
Weibel-Palade bodies that is responsible for the initiation of leukocyte rolling. [1] It is up regulated 
earliest during venous thrombosis and demonstrated in animal models to promote vein wall inﬂ  amma-
tion. [2] Exposure to an activating stimulus such as thrombin or histamine results in the translocation 
of P-selectin to the surface of platelets and endothelial cells in a ligand-receptive form. [3, 4] P-selectin 
glycoprotein ligand 1 (PSGL-1) is a homodimeric mucin found on the majority of leukocytes and is 
also present in small amounts on platelets. [4,35–36] The binding of P-selectin to PSGL-1 initiates a 
signal pathway involving tyrosine phosphorylation, MAP Kinase activation and αmB2 binding activity. 
This signaling mediates leukocyte-endothelial cell, leukocyte-platelet, leukocyte-leukocyte and, to a 
lesser degree, platelet-endothelial interactions.
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Once in vivo transmembrane P-selectin is redis-
tributed onto the surface of activated endothelial 
cells, it mediates leukocyte rolling and initiates the 
inﬂ  ammatory cascade. [7, 19] During thrombosis, 
the P-selectin expressed on activated platelets pres-
ent in a thrombus then supports the recruitment of 
leukocytes. [7, 20] In animal models of thrombosis, 
P-selectin expression has also been demonstrated 
to regulate ﬁ  brin deposition and thrombus size. 
[4, 20, 33] Speciﬁ  cally, mice expressing elevated 
levels of P-selectin have been found to be throm-
bophilic and P-selectin based therapy has been 
demonstrated to correct a mouse model of hemo-
philia A. [4, 7, 34]
In addition to transmembrane P-selectin, a 
soluble form of P-selectin (sP-sel) may be secreted 
into the circulation. [5] It may originate from either 
an alternatively spliced form found in platelets and 
endothelial cells (lacking a transmembrane 
domain) [6, 7] or, may be proteolytically cleaved 
from the cell membrane shortly after activation 
and therefore may reflect platelet activation. 
[7–10]. Thus, it has been postulated that plasma 
levels of sP-sel may predict thrombotic consump-
tive platelet disorders and also may reﬂ  ect endo-
thelial cell activation. [7, 11–16] Conversely, other 
hypotheses speculating on the exact function of 
sP-sel have included an anti-inﬂ  ammatory role in 
which sP-sel directly binds PSGL-1 on leukocytes 
thereby preventing leukocyte-vessel wall interac-
tions. This sP-sel interaction with activated leuko-
cytes may reduce their ability to adhere to 
endothelium in vivo. [7, 22–25] In humans, soluble 
P-selectin appears to be elevated in atherosclerosis 
and may be predictive of future adverse cardiovas-
cular events. [4, 17–18] 
Subramaniam et al. demonstrated that P-selec-
tin deﬁ  cient mice exhibited a slightly prolonged 
bleeding time and an increased hemorrhagic 
response in a local Shwartzman-like reaction sug-
gesting a role for P-selectin in hemostasis. [7, 21] 
This reaction was induced by injections of bacterial 
lipopolysaccharide followed by injections of TNF-
α into the same skin site one day later and resulted 
in microthrombi, vascular injury, and hemorrhage 
at the site of injection. These ﬁ  ndings have been 
supported by a study by André et al. that examined 
the hemostatic properties of mice genetically engi-
neered to express P-selectin without the cytoplas-
mic domain (ΔCT mice). [7] In these mice, 
P-selectin was constitutively expressed on the 
surface of the endothelial cell and shed from the 
plasma membrane resulting in a 3- to 4-fold 
increase of sP-sel in the animals’ plasma. Increased 
levels of sP-sel appeared to accelerate hemostasis 
in these mice by activating the coagulation process 
through the generation of circulating microparticles 
in plasma. Similarly, it was noted that wild-type 
(WT) animals infused with a P-selectin-Ig fusion 
protein (P-sel-Ig) chimera entered a pro-coagulant 
state as well. 
Several studies have demonstrated elevated 
P-selectin in patients with deep venous thrombosis 
(DVT). [4, 37–38] Rectenwald et al. measured 
P-selectin levels in 21 patients with DVT and 
compared these values to 30 healthy controls and 
noted them to be elevated at 88.7 ng/mL (compared 
to 22.1 ng/mL). [4] In a separate study in similar 
patients, there was a notable decrease in P-selectin 
(to 54.5 ng/mL) after 7 days of therapeutic heparin 
therapy. [38]
Microparticles
Microparticles are small fragments of phospholip-
ids of cell membrane that are shed from platelets, 
leukocytes, and endothelial cells and are generally 
less than 1 micron in size that circulate through the 
Table 1. Total US 2002 VTE events—incident & recurrent, fatal & non-fatal.
Event Community-acquired  Hospital-acquired  Total
Non-fatal VTE  193,598  419,825  613,423
 DVT  108,240  268,125  376,365
 PE  85,358  151,700  237,058
Fatal VTE  106,551  189,819  296,370
 DVT  649  1609  2258
 PE  105,902  188,210  294,112
Grand Total  300,149  609,644  909,793
Unpublished 2002 data from the University of Michigan describing the incidence of VTE (venous thromboembolic events) including both 
initial and recurrent episodes; DVT = deep venous thrombosis; PE = pulmonary embolism; events occurring with 90 days after 
hospitalization were categorized as hospital-acquired. Heit JA, Cohen AT, Anderson FA Jr.  Blood 2005; 106(11):abstract #910, p. 267a.
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plasma  of healthy individuals. [4, 26–28] Mic-
roparticles are rich in tissue factor (TF), phospha-
tidylserine and PSGL-1 and thus facilitate and 
amplify coagulation when recruited into a develop-
ing thrombus. [4, 29–31] They also express pro-
thrombinase activity on their membrane [7, 27] 
and monocyte-derived microparticles have been 
shown to activate endothelial cells in vitro leading 
to expression of TF. [7, 32, 33] Elevated levels of 
circulating microparticles have been associated 
with several vascular, inﬂ  ammatory, and coagula-
tion disease processes. Additionally, elevated 
levels of circulating microparticles are associated 
with most cardiac risk factors and appear indicative 
of poor clinical outcome. [66] Platelet derived 
microparticle levels have generally been consid-
ered a marker of platelet activation in cardiovas-
cular disease and studies have demonstrated 
elevations in microparticles associated with high-
risk angiographic coronary obstructive lesions. [65, 
67] Certain elevated microparticle phenotypes may 
also be associated with severity, lesion volume and 
outcome of acute ischemic stroke. [68]
Finally, elevated levels of microparticles have 
been recognized in a murine venous thrombosis 
model. [2, 4] In André et al. study, elevated levels of 
sP-sel in ΔCT mice enhanced the generation of leu-
kocyte-derived microparticles (Mac-1+), some 
(13%) of which also expressed TF. Chirinos et al. 
demonstrated elevated levels of microparticles, 
elevated microparticle-monocyte conjugates, and 
increased platelet activation in patients with venous 
thromboembolism when compared to normal con-
trols. This supports prior studies that suggest released 
elevated microparticles and their binding to mono-
cytes are key events in thrombogenesis. [69]
D-Dimer
Numerous published studies and reviews have 
linked D-dimer, a derivative of cross-linked ﬁ  brin, 
with DVT and PE. In fact, the sensitivity of 
D-dimer for the diagnosis of venous thromboem-
bolism is reported as 96%–98% (96% for the 
diagnosis of DVT). [4, 39–41] Khaira and Mann 
evaluated 80 patients presenting with a clinically 
diagnosed DVT, 29 of which were diagnosed by 
venography. [42] Correlating plasma D-dimer 
levels in this series demonstrated a sensitivity of 
96%, a speciﬁ  city of 40%, a positive predictive 
value of 48%, and a negative predictive value of 
95% when compared to venography. The authors 
further determined that a normal plasma D-dimer 
level could be used as a test of exclusion for DVT. 
Bounameaux et al. applied this concept to aid in 
the detection of pulmonary embolism in a prospec-
tive study involving 171 patients with suspected 
PE with markedly similar results. [40] In the setting 
of PE, D-dimer had a 98% sensitivity and 39% 
speciﬁ  city and it was reported that a “concentration 
below 500µg/l rules out the diagnosis of PE”. In 
2004, Stein et al. systematically reviewed 78 stud-
ies in patients with VTE and correlated D-dimer 
assays with DVT and PE. [39] The authors com-
pared various D-dimer assays and determined that 
the ELISA and quantitative rapid ELISA D-dimer 
assays demonstrated the most clinically useful 
values. A sensitivity of 96% for DVT and 95% for 
PE was reported and the authors reiterated that a 
negative D-dimer assay can safely rule out venous 
thrombosis with high certainty. 
In 2005, Rectenwald et al. hypothesized that 
plasma microparticles, P-selectin, and D-dimer 
levels, alone or in combination with patient risk 
stratiﬁ  cation, would accurately predict the presence 
or absence of DVT when compared to the current 
gold standard of duplex ultrasound examination. 
[4] A total of 73 patients were enrolled in this pilot 
study, of which 30 were healthy controls, 22 had 
acute DVT present on duplex ultrasound and 21 
had clinical symptoms supporting DVT but a 
negative ultrasound. (Tables 2 and 3) The authors 
established threshold values for all the biomarkers 
investigated (including D-dimer) that provided the 
highest sensitivity while maintaining the highest 
speciﬁ  city: soluble P-selectin values of 0.68 ng/mg 
per mg total protein, total microparticles levels 
125% of control, and D-dimer levels of 3 mg/l. 
The preliminary data presented suggested that the 
sensitivity (73%) and speciﬁ  city (81%) of sP-sel, 
total microparticles and d-dimer used in combina-
tion as dichotomous values for diagnosing DVT, 
although less sensitive and speciﬁ  c than duplex 
ultrasound, was an improvement over D-dimer 
alone (64% sensitivity, 76% speciﬁ  city).
More recently, D-dimer levels have been inves-
tigated for use in guiding the length of therapy for 
initial venous thromboembolic events (DVT or 
PE). In 2005, Cosmi et al. investigated D-dimer 
levels in combination with residual venous obstruc-
tion and the risk of recurrence after anticoagulation 
withdrawal for a ﬁ  rst idiopathic DVT. The authors 
reported that the optimal duration of oral antico-
agulation therapy after a ﬁ  rst episode of venous 
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thromboembolism (VTE) is still a matter of debate 
and while extending oral anticoagulation therapy 
reduces the risk of recurrence by 90%, it is associ-
ated with an increased clinically important risk of 
major bleeding. [43, 44] Speciﬁ  cally, this prospec-
tive study examined 400 patients that completed a 
‘therapeutic course’ of oral anticoagulant therapy 
for a ﬁ  rst episode of idiopathic proximal DVT and 
had evidence of residual venous obstruction by 
ultrasound on the day of oral anticoagulant suspen-
sion. D-dimer levels were followed at 30 days and 
the overall recurrence rate was 16.7%. The authors 
demonstrated that abnormal D-dimer levels at one 
month after therapy withdrawal are an independent 
risk factor for recurrent VTE (multivariate hazard 
ratio, HR, of 3.32). They also noted that residual 
venous obstruction on duplex ultrasound at the 
time of oral anticoagulation withdrawal, despite a 
normal or abnormal D-dimer after one month, does 
not inﬂ  uence the rate of recurrence. 
This observation was followed in 2006 by the 
PROLONG study that utilized D-dimer testing to 
determine the duration of anticoagulation therapy. 
[45] 608 patients with a ﬁ  rst episode of symptom-
atic, unprovoked venous thromboembolism were 
examined after completing at least 3 months of 
therapy with warfarin and were followed for a 
mean duration of 1.4 years. The 385 patients with 
normal D-dimer levels at the conclusion of therapy 
did not continue with any further anticoagulant 
treatment, and 4.4% of these patients demonstrated 
a recurrent venous thrombotic event. The 223 
patients with abnormal D-dimer levels were ran-
domized to two groups: 103 resumed anticoagula-
tion and 120 discontinued therapy. 2.9% of those 
patients that continued anticoagulation suffered a 
recurrent thromboembolic event compared to a 
15% recurrence in the non-anticoagulated group. 
In this series, event rates were signiﬁ  cantly higher 
among patients with abnormal D-dimer levels that 
stopped anticoagulation than among those who 
continued anticoagulation (adjusted hazard ratio 
4.26) or among those with normal D-dimer levels 
(adjusted HR 2.27) and the authors support that 
there is a clear beneﬁ  t of prolonged therapy with 
Vitamin K antagonists in patients whose D-dimer 
levels are abnormal one month after the discon-
tinuation of this treatment.
E-Selectin
E-selectin temporally follows P-selectin up-
regulation and has been noted to augment the 
thrombotic response in a murine model of venous 
thrombosis and to amplify the effects of P-selectin. 
[2,46] In 2003, Myers et al. examined 659 male 
Table 2. Use of P-selectin, total microparticles and D-dimer as dichotomous variables for the prediction of 
DVT.
Variables Threshold  value Sensitivity  Speciﬁ  city  Accuracy
Soluble P-selectin  0.68 ng/mg TP  68%  81%  74%
Total microparticles  125% (compared to controls)  50%  67%  58%
D-dimer 3  mg/l  64%  76%  70%
Combined variables     73%  81%  77%
Logistic regression evaluating DVT and symptomatic patients using dichotomous variables establishing threshold values for data analysis. 
Adapted from Rectenwald JE, Myers DD, Hawley AE et al. D-Dimer, P-Selectin, and microparticles: Novel markers to predict deep venous 
thrombosis. Thromb Haemost 2005; 94:1312–17.
Table 3. Use of P-selectin, total microparticles and D-dimer as continuous variables for the prediction of DVT.
Variables Sensitivity  Speciﬁ  city  Accuracy
Soluble P-selectin  71%  81%  76%
Total microparticles  59%  62%  61%
D-dimer 54%  81%  67%
Combined variables  81%  62%  71%
Combined variables+ risk score  62%  57%  60%
Logistic regression evaluating DVT and symptomatic patients using continuous variables. Adapted from table 4, Rectenwald JE, Myers DD, 
Hawley AE et al. D-Dimer, P-Selectin, and microparticles: Novel markers to predict deep venous thrombosis. Thromb Haemost 2005; 
94:1312–17.
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mice that underwent IVC ligation to induce throm-
bosis. For this experiment, mice were separated 
into 4 groups: wild type controls (WT), mice with 
elevated circulating levels of soluble P-selectin 
(Δ-CT), P-selectin gene-interrupted knockout mice 
(PKO) and E- and P-selectin gene-interrupted mice 
(EPKO). As previously noted, the Δ-CT mice gen-
erated 50% more thrombus than wild type mice. 
All mice demonstrated a doubly-labeled leukocyte 
(MAC-1) and platelet (CD41)-derived micropar-
ticle (MP) population with the exception of the 
EPKO mice which produced a primarily platelet-
derived, and a smaller leukocyte-derived, MP 
population with an associated signiﬁ  cant decrease 
in thrombus mass. 
Jilma et al. more recently has demonstrated that 
homozygosity of the single nucleotide polymor-
phism Ser128Arg in the E-selectin gene in humans 
may be associated with recurrent venous throm-
boembolism. [47] This polymorphism alters ligand 
afﬁ  nity, enhances myeloid cellular tethering, and 
regulates leukocyte-endothelial cell interactions 
in vitro. [47–50] E-selectin polymorphism has been 
associated with enhanced endotoxin-triggered, 
tissue factor-mediated coagulation in humans, 
atherosclerosis, myocardial infarction and re-
stenosis after angioplasty and may be associated 
with recurrent VTE. [47, 50–55] In this study, 585 
patients with a ﬁ  rst idiopathic VTE were prospec-
tively examined of which 102 (17%) were hetero-
zygous for the Ser128Arg mutation and 11 (2%) 
were homozygous. Of the total patient population, 
90 patients (15% of 585 patients) demonstrated a 
recurrent VTE. Homozygosity for this mutation 
appeared to increase the cumulative likelihood for 
early recurrent VTE and was considered an inde-
pendent predictor or recurrent VTE (HR 4.1) 
compared to a HR of 1.1 for the heterozygous 
population. 
Thrombin
Generation of thrombin is a well established pivotal 
step of hemostasis. It is also clear that there are 
various risk factors for thrombin generation that 
are associated with recurrent VTE. [56] Because 
of the observation that reduced thrombin genera-
tion has been recorded in patients with bleeding 
tendencies and increased thrombin generation has 
been noted in patients at risk for VTE, Hron et al. 
hypothesized that by measuring thrombin genera-
tion, patients with VTE could be stratiﬁ  ed into 
high- and low-risk categories for recurrence. The 
authors prospectively examined 914 patients with 
a ﬁ  rst, spontaneous VTE and assessed the relation-
ship between thrombin generation and risk of 
recurrence. They found that 100 patients (11%) 
suffered recurrent VTE and that patients without 
recurrent VTE had lower thrombin generation (as 
measured by a commercially available thrombin 
assay system) than those with recurrence (mean 
349.2 nM compared to 419.5 nM, p = <0.001). 
Moreover, when compared to patients with throm-
bin generation >400 nM, those with values between 
300–400 nM had a relative risk of recurrence of 
DVT of 0.42 and this further decreased to 0.37 for 
those patients with values <300 nM. Even after 
four years, the probability of recurrence was still 
reduced at 6.5% among patients with thrombin 
generation <400 nM (2/3 of patients) compared to 
20% for values >400 nM. This suggests that 
patients with values <400 nM probably do not 
beneﬁ  t from indeﬁ  nite therapy with vitamin K 
antagonists.
Interleukin-10
Interleukin-10 (IL-10) is a major immunoregulatory 
and anti-inﬂ  ammatory cytokine with a highly poly-
morphic promoter gene with two polymorphic 
dinucleotide repeats (IL-10G and IL-10R microsat-
telites). [59–63] It has been suggested that these 
polymorphisms may play a role in the onset of 
various autoimmune and lymphoproliferative disor-
ders. [59] Animal models have demonstrated that 
IL-10 modulates the development of DVT. [59, 64] 
Cochery-Nouvellon et al. recently conducted a 
human case-control study to evaluate whether IL-10 
polymorphisms is a risk factor for venous thrombo-
sis as this pathology is certainly associated with a 
consistent inﬂ  ammatory state. They compared 74 
patients with at least one episode of venous throm-
bosis to 100 healthy controls and conducted multi-
variate logistic regression analysis. The authors 
demonstrated that IL-10 G13 and G10 alleles are 
independent risk factors for venous thrombosis 
(Odds ratio 3.33 and 2.83 respectively). Furthermore, 
they found that the IL-10 G10 allele was more fre-
quent in recurrent disease suggesting that it may be 
an independent risk factor for recurrent disease.
Fibrin Monomers
Vogel and Spanuth assessed ﬁ  brin monomers as 
markers of intravascular activation of the coagulation 
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system resulting in disseminated intravascular 
coagulation or deep venous thrombosis. [70] Spe-
ciﬁ  cally, elevated levels of ﬁ  brin monomers fol-
lowing orthopedic surgery were determined to have 
a 63–73% positive predictive value for the diagno-
sis of post-operative DVT, possibly allowing for 
early detection of a prethrombotic state and pre-
event prophylaxis. While ﬁ  brin monomers more 
recently are felt to be inferior to D-dimer assays as 
a primary screening tool for DVT, they may aid in 
this diagnosis when combined with both ultrasound 
and D-dimer assays. [71]
Conclusion
Historically, the diagnosis of acute venous throm-
boembolism (DVT and PE) has relied on primarily 
imaging modalities to establish the diagnosis of 
VTE. A multi-modality approach, involving not only 
imaging but also serology, is currently evolving. 
There is mounting evidence to support the use of 
certain serum “biomarkers” (i.e. selectins, micropar-
ticles, thrombin, D-dimer, and IL-10) that may aid 
in this diagnosis and treatment of DVT and PE. 
Regardless of the difﬁ  culties in diagnosis of VTE, 
issues surrounding the management of patients with 
VTE and the duration of treatment remain problem-
atic. Currently, a third of patients will experience 
recurrent VTE within the next 5 to 8 years with an 
associated 5% case-fatality rate of recurrence of 
VTE in patients that have completed standard treat-
ment. [56–58] Recent studies support that these 
same biomarkers may not only aid in diagnosis, but 
may in the future help guide venous thromboem-
bolic therapy by identifying patients at high risk of 
recurrence that may benefit from prolonged or 
indeﬁ  nite therapy with anticoagulation. In next few 
years, biomarkers may help predict which thrombi 
will resolve spontaneously or recanalize, and those 
that will not—potentially identifying patients that 
would beneﬁ  t from more aggressive therapies than 
standard anticoagulation.
Prepared for; Biomarker Insights, ed. Kingsmore, 
SF. Liberatas Academica, Aukland, NZ.
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